Literature DB >> 21306565

Hla-B alleles and lamotrigine-induced cutaneous adverse drug reactions in the Han Chinese population.

Yi-Wu Shi1, Fu-Li Min, Xiao-Rong Liu, Li-Xuan Zan, Mei-Mei Gao, Mei-Juan Yu, Wei-Ping Liao.   

Abstract

Lamotrigine (LTG) is a commonly used antiepileptic drug. However, the use of LTG is limited because of its cutaneous adverse drug reactions (cADRs) ranging from mild maculopapular eruption (MPE) to severe Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). A strong association between HLA-B*1502 and carbamazepine-induced SJS/TEN has been identified in Chinese and Thai. Although three of seven cases with HLA-B*1502 have been reported in LTG-induced SJS/TEN so far, the relationship between HLA-B*1502 and LTG-induced SJS/TEN needs further investigation. It is also unclear whether there is a specific genetic marker associated with LTG-induced MPE in Chinese. In this study, we genotyped 43 Han Chinese patients treated with LTG (14 cases with LTG-induced cADRs and 29 LTG-tolerant controls), using PCR-SSP for HLA-B*1502 testing and low-resolution genotyping, as well as sequencing for four-digit genotyping. The two cases with SJS were negative for HLA-B*1502, with B1301/1301 and 4601/5610, respectively. Combining the data with previous studies, there was no significant difference in the frequency of subjects with HLA-B*1502 between the LTG-induced SJS/TEN group and the LTG-tolerant group (p = 0.08, OR 4.23, 95% CI 0.94-18.97). In the MPE group, only one was positive for HLA-B*1502. There was no significant difference in the frequency of a specific HLA-B allele between the MPE group and the LTG-tolerant group either. In this study, no significant association between HLA-B*1502 and LTG-induced SJS or MPE was found. Given the small sample size and only HLA-B locus genotyping, further large-scale studies are required to explore genetic associations with LTG-induced cADRs.
© 2011 The Authors. Basic & Clinical Pharmacology & Toxicology © 2011 Nordic Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21306565     DOI: 10.1111/j.1742-7843.2011.00681.x

Source DB:  PubMed          Journal:  Basic Clin Pharmacol Toxicol        ISSN: 1742-7835            Impact factor:   4.080


  22 in total

1.  Carbamazepine hypersensitivity: progress toward predicting the unpredictable.

Authors:  Barry E Gidal
Journal:  Epilepsy Curr       Date:  2011-11       Impact factor: 7.500

Review 2.  Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity.

Authors:  Volker M Lauschke; Yitian Zhou; Magnus Ingelman-Sundberg
Journal:  Pharmacol Ther       Date:  2019-01-22       Impact factor: 12.310

Review 3.  Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy.

Authors:  Rebecca Pavlos; Simon Mallal; David Ostrov; Yuri Pompeu; Elizabeth Phillips
Journal:  J Allergy Clin Immunol Pract       Date:  2014 Jan-Feb

4.  HLA-B*51:01 is strongly associated with clindamycin-related cutaneous adverse drug reactions.

Authors:  Y Yang; S Chen; F Yang; L Zhang; G Alterovitz; H Zhu; J Xuan; X Yang; H Luo; J Mu; L He; X Luo; Q Xing
Journal:  Pharmacogenomics J       Date:  2016-08-16       Impact factor: 3.550

5.  PharmGKB summary: very important pharmacogene information for human leukocyte antigen B.

Authors:  Julia M Barbarino; Deanna L Kroetz; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2015-04       Impact factor: 2.089

6.  Genome-wide mapping for clinically relevant predictors of lamotrigine- and phenytoin-induced hypersensitivity reactions.

Authors:  Mark McCormack; Thomas J Urban; Kevin V Shianna; Nicole Walley; Massimo Pandolfo; Chantal Depondt; Elijah Chaila; Gerard D O'Conner; Dalia Kasperavičiūtė; Rodney A Radtke; Erin L Heinzen; Sanjay M Sisodiya; Norman Delanty; Gianpiero L Cavalleri
Journal:  Pharmacogenomics       Date:  2012-03       Impact factor: 2.533

Review 7.  HLAs: Key regulators of T-cell-mediated drug hypersensitivity.

Authors:  A J Redwood; R K Pavlos; K D White; E J Phillips
Journal:  HLA       Date:  2018-01       Impact factor: 4.513

Review 8.  Pharmacogenomics of off-target adverse drug reactions.

Authors:  Sarah L Garon; Rebecca K Pavlos; Katie D White; Nancy J Brown; Cosby A Stone; Elizabeth J Phillips
Journal:  Br J Clin Pharmacol       Date:  2017-04-27       Impact factor: 4.335

Review 9.  Severe Delayed Drug Reactions: Role of Genetics and Viral Infections.

Authors:  Rebecca Pavlos; Katie D White; Celestine Wanjalla; Simon A Mallal; Elizabeth J Phillips
Journal:  Immunol Allergy Clin North Am       Date:  2017-11       Impact factor: 3.479

Review 10.  Evolving models of the immunopathogenesis of T cell-mediated drug allergy: The role of host, pathogens, and drug response.

Authors:  Katie D White; Wen-Hung Chung; Shuen-Iu Hung; Simon Mallal; Elizabeth J Phillips
Journal:  J Allergy Clin Immunol       Date:  2015-08       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.